Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
Cancer Chemotherapy and Pharmacology
|
April 19, 2014
Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors
Ramon Salazar, Serafin Morales, Marta Gil-Martín, et al.
Investigational New Drugs
|
February 12, 2013
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)
Harry P Erba, Hamid Sayar, Mark Juckett, et al.
Investigational New Drugs
|
March 4, 2021
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma
Marjorie G Zauderer, Evan W Alley, Johanna Bendell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 12, 2018
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer
Johanna C Bendell, Anna M Varghese, David M Hyman, et al.
Theranostics
|
July 21, 2011
Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients
Azeem Saleem, Julian C Matthews, Malcolm Ranson, et al.
British Journal of Clinical Pharmacology
|
January 25, 2019
Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease
Matthew Sheetz, Philip Barrington, Sophie Callies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2011
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer
David S Hong, Razelle Kurzrock, Yun Oh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2008
Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study
Stephan A Veltkamp, Robert S Jansen, Sophie Callies, et al.
Investigational New Drugs
|
September 18, 2015
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors
Sandrine J Faivre, Anthony J Olszanski, Karin Weigang-Köhler, et al.
Journal of Hematology & Oncology
|
March 23, 2017
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia
Saroj Vadhan-Raj, Rafat Abonour, Jonathan W Goldman, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
Cancer Chemotherapy and Pharmacology
|
April 19, 2014
Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors
Ramon Salazar, Serafin Morales, Marta Gil-Martín, et al.
Investigational New Drugs
|
February 12, 2013
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)
Harry P Erba, Hamid Sayar, Mark Juckett, et al.
Investigational New Drugs
|
March 4, 2021
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma
Marjorie G Zauderer, Evan W Alley, Johanna Bendell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 12, 2018
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer
Johanna C Bendell, Anna M Varghese, David M Hyman, et al.
Theranostics
|
July 21, 2011
Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients
Azeem Saleem, Julian C Matthews, Malcolm Ranson, et al.
British Journal of Clinical Pharmacology
|
January 25, 2019
Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease
Matthew Sheetz, Philip Barrington, Sophie Callies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2011
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer
David S Hong, Razelle Kurzrock, Yun Oh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2008
Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study
Stephan A Veltkamp, Robert S Jansen, Sophie Callies, et al.
Investigational New Drugs
|
September 18, 2015
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors
Sandrine J Faivre, Anthony J Olszanski, Karin Weigang-Köhler, et al.
Journal of Hematology & Oncology
|
March 23, 2017
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia
Saroj Vadhan-Raj, Rafat Abonour, Jonathan W Goldman, et al.
Page
of 3